BMRN

60.4101.64%
MJ

Mark Joseph Enyedy

Independent Director

Mr. Mark Joseph Enyedy, J.D., is Independent Director at Charles River Laboratories International Inc. Since May 20, 2025. Mr. Enyedy serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. He is Independent Outside Director of Astellas Pharma Inc. since June 2025. He is Non-Executive Director at Ergomed plc since June 10, 2021. He had been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 until February 2024 and served as its Interim Principal Financial Officer since November 26, 2018. Mr. Enyedy served as an Independent Director of LogicBio Therapeutics, Inc. since March 17, 2020 until November 16, 2022. He has combined general management, business development and legal experience in the biotechnology industry across multiple therapeutic areas including executive management, corporate development and legal roles, across multiple therapeutic areas with a focus on rare diseases and oncology. He served as Head of Corporate Development at Shire plc since January 1, 2015 to until May 13, 2016 and served as its Company Secretary and Executive Vice President. He joined Shire in 2013 and served as its Internal Medicine Business Unit Head from August 2013 to April 2014. Mr. Enyedy served as the Interim General Counsel of Shire plc from January 1, 2015 to June 15, 2015 and led its Strategy, M&A and Corporate Planning functions and provided commercial oversight for its pre-Phase 3 portfolio. He served as the Chief Executive Officer of Proteostasis Therapeutics, Inc from 2011 to 2013. He joined Proteostasis after serving few years at Genzyme Corporation. He began his career at Genzyme Corporation in 1996 as Corporate Counsel, where he was responsible for overseeing corporate collaborations, merger and acquisition activities, financings and securities law compliance. He served as the President of Transplant, Oncology & multiple sclerosis divisions and Senior Vice President at Genzyme Corporation. Mr. Enyedy served as President of the Transplant, Oncology and Multiple Sclerosis division for Genzyme Oncology, Inc. Mr. Enyedy served as Senior Vice President and General Manager of Genzyme Molecular Oncology at Genzyme Corporation since July 16, 2003. He served as Vice President of Business Development for Genzyme Corporation, where he completed over twenty transactions, including Purdue Pharma L.P. He provided senior level transactional support for Genzyme Corporation's other therapeutic franchises. Mr. Enyedy served as the Director of Business Development in Genzyme's Oncology Division. He served as Vice President of Business Development at Vertex Pharmaceuticals Incorporated since February 3, 2003. He oversaw Vertex's business development organization at its Cambridge, MA, Headquarters. From 1990 to 1996, he worked as an Associate in the business law department at Palmer & Dodge, LLP, where he represented biopharmaceutical companies in acquisition, Partnering and financing transactions. He had been an Independent Director of Akebia Therapeutics, Inc. since December 12, 2018 until June 2, 2021. He was an Independent Director at Keryx Biopharmaceuticals, Inc. since September 13, 2017 until December 12, 2018. He had been a Director of ImmunoGen, Inc. since May 16, 2016, until February 12, 2024. He serves as a Director of Immunogen BioPharma (Ireland) Limited, Immunogen Europe Limited and Immunogen Securities Corp. He was a Director of Fate Therapeutics, Inc. since July 2012 until May 2, 2018. He served as a Director of Proteostasis Therapeutics, Inc. Mr. Enyedy also serves on the Boards of Directors of The American Cancer Society of Eastern New England. Mr. Enyedy holds a BS in criminal justice from Northeastern University and a J.D. from Harvard Law School. He is also a Member of the Board of Directors of the Biotechnology Innovation Organization (BIO), the world's largest advocacy organisation representing the biotechnology industry in the US and globally.

Positions